KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- GAO Releases Report on States’ Regulation of PBMs April 19, 2024Representatives from the US Government Accountability Office (GAO) interviewed regulators from 5 states on pharmacy benefit manager laws.
- AI Guided Care Plans Streamline Workflow and Improve Patient Care April 19, 2024When AI is incorporated into pharmacy workflows, the technology can help pharmacists demonstrate the value of their profession.
- Enhancing Patient-Pharmacist Relationships Through Conversation April 19, 2024Listening carefully to determine what’s beneath the surface of a patient’s concerns can make a world of difference in providing quality care.
- Medicare-Focused Insurance Agency Could Benefit Independent Pharmacies April 19, 2024A Q&A with Joe McKamey, general manager at Marcrom’s Pharmacy in Manchester, Tennessee.
- Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval April 19, 2024
- Swipe Right on Wellness: The Rise of Digital Therapeutics in Mental Health April 19, 2024Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.
- CVS Pharmacists in Rhode Island Petition to Unionize April 18, 2024Nine pharmacists from 2 corporate locations in Wakefield and Westerly are seeking to join the Pharmacy Guild in an attempt to improve working conditions.
- Pharmacies Should Adopt Proactive Health, Wellness to Help Patients April 18, 2024Kathy Campbell, PharmD, discusses why she believes wellness and proactive health are the future of pharmacy and the unique value they offer compared to traditional models.
- How Differences in Bispecific Therapies Impact Myeloma Treatment Operations April 18, 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
- Myeloma Expert: Earlier Use of Bispecifics Can Improve Patient Outcomes April 18, 2024As the potential grows to use emerging bispecifics in earlier lines of myeloma therapy, so does the potential to induce better patient outcomes, said Kirollos Hanna, PharmD.
Pharmacy Times articles
- Study Examining Glofitamab With GemOX in Patients With R/R DLBCL Meets Primary Endpoint April 19, 2024Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.
- FDA Approves Alectinib to Treat Patients With ALK-Positive NSCLC April 19, 2024With this approval, alectinib is the first anaplastic lymphoma kinase inhibitor to be approved for patients with ALK-positive, early-stage non-small cell lung cancer.
- Positive Data Demonstrates Gepotidacin is Non-Inferior to Alternative Treatment in GC April 19, 2024In a trial that compared gepotidacin to ceftriaxone plus azithromycin in patients with urogenital gonorrhea, gepotidacin presented a 92.6% microbiological success rate.
- Study: Chemotherapy to Treat Breast Cancer Increases Risk of Lung Cancer April 19, 2024Individuals treated with chemotherapy following a breast cancer diagnosis were more at risk of developing second primary lung cancer.
- Questions Remain About How Pharmacists Can Integrate Into Food Pharmacies April 19, 2024Regardless of how this fits into workflow, pharmacists can play a significant role in counseling patients on nutrition and holistic health.
- Gap in Medicaid Impacts Access to Services for Justice-Involved Patients April 19, 2024Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases
- Climate Change Increases Rate of Infectious Diseases, Expert Says April 18, 2024Speaker Monica Diaz describes the detrimental impact climate change has on the transmission and increases in infectious disease cases.
- Aurigene Pharmaceutical Services Ltd., and Vipergen announce a strategic partnership for offering DNA encoded library (DEL) screening and integrated drug discovery services April 18, 2024The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein.
- Durvalumab With Chemotherapy Shows Long-Term Overall Survival at 3 Years April 18, 2024The results were the longest survival follow-up ever reported for a phase 3 trial for biliary tract cancer.
- Middletown Pharmacy and Wellness Staff Care for the Community April 18, 2024Tara Schneider, PharmD, and her husband, Chuck Schneider, MBA, offer expanded clinical services in their Louisville, Kentucky, pharmacy.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com